IP Library › Granted Patent US 12,023,384
Granted Patent B2
US 12,023,384 · App. 16/892,588 · Granted Jul 2, 2024

Immunogenic peptides comprising an MHC class II T cell epitope and a redox motif

Inventors: Jean-Marie Saint-Remy (Grez-Doiceau, BE); Vincent Carlier (Enines, BE); Luc Vander Elst (Obaix, BE); David Burkhart (Victor, MT)
Assignee: IMCYSE SA
A61K47/646A61K39/0008A61K39/385A61P25/00A61P37/02C07K14/4713C07K14/70539A61K2039/572A61K2039/6031A61K2039/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,023,384
App. No.
16/892,588
Granted
Jul 2, 2024
Kind
B2
Abstract

The invention relates to isolated immunogenic peptides comprising a MHC class II T cell epitope, and immediately adjacent or separated from said epitope a H-X(0,2)-C-X(2)-[CST] or [CST]-X(2)-C-X(0,2)-H redox motif.

Claims (14)

1. An isolated immunogenic peptide of between 13 and 50 amino acids comprising

(a) a human MHC class II T cell epitope of an antigen, said epitope having a length of between 8 and 16 amino acids that binds into the cleft of the human MHC class II molecule, and

(b) a redox motif consisting of H-X(0,2)-C-X(2)-[CST] [SEQ ID NO: 78, 90 or 91] or [CST]-X(2)-C-X(0,2)-H [SEQ ID NO: 79, 92 or 93], wherein H is His, C is Cys, S is Ser, T is Thr and X is any amino acid,

wherein said human MHC class II T cell epitope is immediately adjacent to said redox motif or separated from said redox motif by a linker of at most 7 amino acids,

with the proviso that said antigen does not contain in its sequence said redox motif within a distance of 10 amino acids of said epitope.

2. The peptide according to claim 1 , with the proviso that said antigen does not contain in its sequence said redox motif.

3. The peptide according to claim 1 , wherein said redox motif is located N terminally from the human MHC class II T cell epitope.

4. The peptide according to claim 1 , wherein said peptide has a length of between 13 and 30 amino acids.

5. The peptide according to claim 1 , wherein the linker comprises at most 4 amino acids.

6. The peptide according to claim 1 , wherein the MHC class II T cell epitope is separated from said redox motif by 2 amino acids.

7. The peptide according to claim 1 , wherein X within the C-X(2)-[CST] (SEQ ID NO: 76) or [CST]-X(2)-C(SEQ ID NO: 77) sequence is Gly or Pro.

8. The peptide according to claim 1 , wherein X within the C-X(2)-[CST] (SEQ ID NO: 76) or [CST]-X(2)-C(SEQ ID NO: 77) sequence is not Cys.

9. The peptide according to claim 1 , wherein the at most 2 amino acids separating said histidine and said C-X(2)-[CST] (SEQ ID NO:76) or [CST]-X(2)-C (SEQ ID NO: 77) sequence do not comprise Cys, Ser or Thr.

10. The peptide according to claim 1 , wherein the redox motif consisting of H-C-X(2)-[CST] [SEQ ID NO: 78] or [CST]-X(2)-C-H [SEQ ID NO: 79].

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2024
From: SAINT-REMY, JEAN-MARIE
To: IMCYSE SA
Reel/Frame 066810/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: CARLIER, VINCENT; VANDER ELST, LUC; BURKART, DAVID
To: IMCYSE SA
Reel/Frame 052843/0885 →
Priority Claims (1)
GB 1418433 · Oct 17, 2014 · national
Continuity (2)
Continuation 15516045
Related Publication 20200397911A1 · Dec 24, 2020
Cited By (1)
US 12,583,891